Archive: 2026/02 - Page 2
Bioequivalence standards for generic drugs have long ignored batch-to-batch variability, risking false conclusions. New guidelines now require multi-batch testing to ensure real-world equivalence and patient safety.
Biosimilars aren't exact copies of biologics - tiny manufacturing differences can trigger immune responses. Learn why some patients develop antibodies, how administration and genetics affect risk, and what real-world data really shows.
Medications
Archives
Recent-posts
Foreign Manufacturing of Generics: FDA Oversight and Standards in 2025
Dec, 17 2025
Panmycin (Tetracycline) vs Alternative Antibiotics: Detailed Comparison
Oct, 17 2025
How Hypocalcemia and Hypomagnesemia Influence Each Other
Oct, 3 2025
2025 Alternatives for Prelone: A Practical Guide
Feb, 28 2025
Medication-Induced Acute Angle-Closure Glaucoma: Recognizing the Eye Emergency
Apr, 4 2026